Catalyst Biosciences recently announced updated positive interim data from a phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneously administered factor VIIa therapy.
An interview with one of the recipients of NHF's Innovative Investigator Awards
The company reported on preliminary data from the Phase 1/2 clinical trial designed to evaluate SB-525, the company’s gene therapy program for people with hemophilia A, or factor VIII (FVIII) deficiency.
The therapy is administered via a one-time intravenous infusion, which is designed to elicit the production of therapeutic levels of factor VIII.
The preliminary injunction was part of an ongoing patent lawsuit.
The activity will examine the technology behind the emerging approaches to gene therapy in hemophilia.
The company stated that it is their intent to provide enough advanced notice of the discontinuation to allow patients to transition to a suitable alternative therapy
This CME and CNE-accredited activity reviews the basic science behind the development of inhibitor antibodies to treatment for hemophilia, and more.
A new patient financial assistance program has become available for individuals with hemophilia.
HANDI, NHF’s information resource center, highlights resources aimed for new college students.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car